Kadmon Pharmaceuticals and Nano Terra enter into exclusive licensing agreement for drug product candidates and drug discovery platform
Kadmon Pharmaceuticals LLC ("Kadmon"), a biopharmaceutical company focused on developing medicines and therapies in the areas of oncology, infectious diseases, and immunology, has entered into an agreement with research and development company Nano Terra, Inc. ("Nano Terra"), whereby Kadmon would acquire Nano Terra's perpetual, worldwide exclusive licenses to three novel, clinical stage product candidates and rights to its drug discovery platform, Pharmacomer Technology. Although specific terms of the agreement were not disclosed, but the companies did note that the licenses for the product candidates and the Pharmacomer technology platform will be transferred to NT Life Sciences, a newly formed joint venture co-owned by the companies.
The product candidates and technology platform "focus on breakthroughs in the functionality of pharmaceuticals at the molecular level which enable the discovery of new, small molecule drugs optimized to meet the challenges of human physiology and to evade the early development challenges of traditional medicinal chemistry practices."
